We present a case of death likely to be directly due to cyclosporine (CsA) neurotoxicity. To date, there have been no reports of deaths directly due to CsA neurotoxicity, nor has an associated histological lesion been described independent of confounding processes. A 54-year-old male received an HLA-matched-unrelated BMT for CML. He developed progressive encephalopathy and on day ؉79 had a generalized seizure. All CSF studies were negative for infectious causes. MRI revealed diffuse, symmetrical white matter abnormalities located in the occipital sub-cortex, thalamus, mid brain, pons, and cerebellum which were typical of CsA toxicity. The patient died of central respiratory failure within 72 h of discontinuing CsA. Autopsy revealed diffuse patchy white matter edema and astrocytic injury without evidence of axonopathy, demyelination, microvascular injury, or infectious/inflammatory process. This case demonstrates previously undescribed lethal CsA neurotoxicity and may reveal an associated primary pathological lesion. Keywords: cyclosporine; neurotoxicity; MRI; CML; allogeneic bone marrow transplant Neurological complications cause morbidity and mortality in up to 37% of patients following allogeneic bone marrow transplantation.
Neurological complications cause morbidity and mortality in up to 37% of patients following allogeneic bone marrow transplantation. 1 Case reports and retrospective case series implicate CsA neurotoxicity as a significant contributor to these complications. 1, 2 This toxicity can range from the most common finding of tremors to the most severe syndrome of seizures, visual disturbances, and radiographically characteristic white matter abnormalities often involving the occipital lobes. 2, 3 This distinguishable clinical and radiographic syndrome, however, has not been reported to be directly fatal. [2] [3] [4] Here, we present a patient with typical CsA CNS neurotoxicty, a fatal outcome, and no other overt cause of death. We also describe the previously unreported 
Case report
Philadelphia chromosome-negative CML was diagnosed in June 1996 in a 54-year-old male with adult onset diabetes. In July 1997, while still in chronic phase, he received an HLA-identical unrelated allogeneic BMT following CY/TBI conditioning. He was treated with routine GVHD prophylaxis consisting of CsA/MTX according to the Seattle regimen.
5 Engraftment (Ͼ500 neutrophils) occurred on day ϩ20, and platelet requirements ceased after day ϩ22. His post-transplant course was notable for the development of acute skin GVHD on day ϩ26 not requiring increased immunosuppression and symptomatic biopsyproven upper gastrointestinal GVHD on day ϩ65 requiring treatment with methylprednisolone (1 mg/kg i.v. twice daily).
After complaining of intermittent 'blurred vision' for several days, he was noted by his wife to be confused on day ϩ78. Neurological examination and routine laboratory studies were normal. The following day he was increasingly somnolent. Deep tendon reflexes were symmetrical but plantar reflexes were absent. Otherwise, sensory/motor and cranial nerve examinations were normal. On day ϩ79 he had a single generalized tonic-clonic seizure that was treated with phenytoin. Non-contrast brain computerized tomography was normal. Repeat laboratory studies were normal with a therapeutic cylosporine level of 328 ng/ml. Cerebrospinal fluid (CSF) studies revealed normal protein and glucose, one lymphocyte and a negative gram stain. He was empirically treated with ceftriaxone, acyclovir, and ampicillin while awaiting culture results.
The patient's mental status continued to deteriorate with increasing combativeness, perseveration, and diffuse hypertonia hindering the attainment of a brain MRI. On day ϩ81, an MRI revealed a diffuse white matter signal abnormality extending throughout the brain on flair images ( Figure 1 ). This pattern involved the subcortical cerebral white matter in a symmetric fashion as well as bilateral thalamus, mid brain, pons and cerebellar hemispheres. It was considered to be consistent with CsA-induced neurotoxicity and less likely with viral encephalitis. On day ϩ83 CSF studies, including PCR for HSV, VZV, CMV and HHV-6, revealed no evidence of viral, bacterial, or fungal pathogens. CsA and all antibiotics were discontinued and he was started on FK-506. His neurological status continued to deteriorate with worsening encephalopathy, responses only to painful stimuli, and development of Cheyne-Stokes respiration. His family requested that he not be intubated or resuscitated. On day ϩ86 repeat brain MRI revealed increased prominence of the white matter signal abnormalities. He continued to deteriorate with development of decorticate posturing and an agonal respiratory pattern and died on day ϩ87.
An autopsy was performed within 8 h of the patient's death. The brain was mildly heavy (1490 g) with no grossly evident lesions on serial horizontal sections. Histology revealed diffuse patchy edema in deep cerebral, deep cerebellar, and brainstem white matter. There was no associated cell necrosis, cytopathic effect, or inflammatory cell infiltrate. Special stains revealed good preservation of myelinated nerve fibers without evidence of axonopathy or demyelination. Glial fibrillary acidic protein (GFAP) staining revealed uniformly distributed astrocytic cells in expected numbers with slightly more staining in cell bodies and adjacent processes but little appreciable staining around microvascular structures. Electron microscopy of edematous white matter revealed evidence of astrocytic injury with loss of cell processes between myelinated nerve fibers and foot processes around otherwise intact microvascular structures ( Figure 2) . Fibrin was attached to the glial aspects of perivascular basement membranes, at sites devoid of astrocytic foot processes. Microvascular endothelium and nerve fiber cells had changes consistent with edema and the postmortem state. Cultures of fresh brain tissue were negative for viruses, bacteria, and fungi. There were no other clinically significant or adverse findings as autopsy; bone marrow appeared normal, and typical inflammatory cell infiltrates were present at sites of acute but mild aspiration pneumonia (1-2 days).
Discussion
This patient had the typical clinical findings and MRI abnormalities of CsA neurotoxicity. 3, 4 Infectious and metabolic causes of progressive encephalopathy were excluded. He probably had symptoms of CsA neurotoxicity with his earliest complaint of 'blurred vision'. As previously described, CsA levels do not correlate with toxic complications. In fact, only 18% of patients with neurotoxicity in one series had elevated CsA levels. 6 Although most reported patients have recovered from this toxic effect, the duration of CsA neurotoxicity has persisted for up to 7 days after discontinuing the drug. 2 This may be attributed to the multiple active metabolites of CsA. 7 CsA levels in this patient were at the lower limit of the therapeutic range and he died within 72 h of discontinuing CsA, well before one would expect resolution of symptoms.
Although deaths directly attributable to CsA neurotoxicity have not been reported previously, case reports and case series have reported deaths of patients with a history of CsA neurotoxicity. In one series of 239 transplant patients, 10 experienced severe CsA neurotoxicity. 2 Of the three that eventually went to autopsy, all died of other specific causes. Only one patient had not had follow-up radiographic evaluation to document resolution of the CNS abnormalities and died from disseminated candidiasis and multiorgan system failure. The case we present was not complicated by other attributable causes of death and occurred within 24 h of MRI demonstration of typical lesions.
There was no evidence of CNS infectious or inflammatory processes in samples of brain removed at autopsy and studied by routine histology, electron microscopy, culture Figure 2 Electron micrograph (7140ϫ) demonstrates typical appearance microvascular structures in the deep, subcortical white matter. An erythrocyte (E) is located in the capillary lumen, which is lined by intact endothelium anchored to intact basement membrane (small arrowhead). Adjacent intact glial basement membrane (large arrowhead) is denuded of astrocytic foot processes. Fibrin (arrows) adheres to the glial aspect of this membrane and is present in the adjacent space also containing myelinated nerve fibers (*).
and PCR analyses. Incidental mild patchy aspiration pneumonia was noted, demonstrating the patient's ability to mount an appropriate inflammatory response. The specific observations of white matter edema with astrocytic cell injury and loss of foot processes correlate with the radiographic images and may suggest the cellular site of CsA neurotoxicity, although another process could have induced astrocytic injury allowing the CsA to cross the blood-brain barrier to exert its toxic effect.
The exact mechanism of CsA neurotoxicity remains unclear although similar findings of specific glial cell toxicity have been demonstrated in differentiated neuronal tissue cultures incubated with CsA. 8 Other authors have proposed hypotheses including vasoconstrictive ischemia possibly due to increased release of endothelin, axonal swelling due to a direct toxic insult, microangiopathic hemolytic anemia or increased free CsA due to lowered lipid binding. 2, 3, 9 These explanations are confounded by the fact that CsA does not readily cross the blood-brain barrier. 10 Animal studies have, however, demonstrated that CsA can induce endothelial damage by interfering with prostacyclin and promoting platelet aggregation. 11, 12 This or other processes could potentially allow CsA to penetrate the bloodbrain barrier and exert its toxic effect. From the available data, however, it is evident that the precise pathophysiology of CsA neurotoxicity has yet to be determined. We conclude that CsA toxicity can result in a fatal outcome due to primary CNS cell injury and central respiratory failure. Clinicians should remain aware of early symptoms of CsA neurotoxicity. We also describe autopsy findings uncomplicated by concomitant CNS processes. This description of astrocytic cell injury with foot process loss in the absence of other consistent CNS abnormalities may illustrate the primary pathological lesion involved with CsA neurotoxicity.
